FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997777254> ?p ?o ?g. }

• W1997777254 endingPage "S322" @default.
• W1997777254 startingPage "S321" @default.
• W1997777254 abstract "Introduction: Azathioprine (AZA) and other immunomodulating drugs are increasingly used in the pediatric IBD-population but also in other autoimmune and inflammatory diseases. Well known side-effects are important to consider. We can anticipate an increase in the frequency of side-effects due to an increasing usage and efforts to individual doseage optimization. EBV-infections are frequently encountered in childhood, often giving rise to transient haematological effects. Thus, an acute EBV-infection in a child on treatment with azathioprine is not an uncommon clinical challange to deal with. The purpose of the study was to highlight the risk of Epstein Barr Virus (EBV) infections in azathioprine (AZA)-treated patients. Methods: We reviewed our patient database to see whether acute tonsillitis caused by an EBV-infection in children on AZA would lead to bone marrow depression. Results: We have recently seen three patients with IBD (age 17–18 years) and EBV. They had been treated with AZA (1.1–1.6 mg/kg/day) for more than 12 months. All had normal laboratory work-up (i.e. hemoglobin, WBC, platelets, hepatic enzymes; AST/ALT) before onset of the infection. All patients had thiopurine methyltransferase (TPMT) activity and thioguanine nucleotide (TGN) concentrations within normal ranges, in two of them tested prior to the infection, and in the third patient after the infection on the same dose of AZA. The three patients presented with signs of tonsillitis and fever. Within 9–24 days after the first signs of infection a neutrophilic granulocytopenia developed (lowest values were 500, 700 and 1.000/mm3, respectively). This was heralded by a thrombocytopenia 4–7 days after the first signs of infection (lowest values were 35.000, 135.000 and 102.000/mm3, respectively). All changed from normal to elevated hepatic enzymes (AST/ALT). Serological testing revealed IgM-positive EBV-infection. AZA was temporarily discontinued. The blood tests were depressed for several weeks, but all recovered 3–6 weeks after the first signs of infection. Conclusion: EBV-infection may have an additive depressing effect on the bone marrow in patients treated with AZA. Early withdrawal of AZA in these situations can prevent serious complications." @default.
• W1997777254 created "2016-06-24" @default.
• W1997777254 creator A5009148625 @default.
• W1997777254 creator A5022234144 @default.
• W1997777254 creator A5032980660 @default.
• W1997777254 creator A5070536643 @default.
• W1997777254 date "2004-06-01" @default.
• W1997777254 modified "2023-09-26" @default.
• W1997777254 title "P0696 EPSTEIN BARR VIRUS INFECTION IN PATIENTS ON AZATHIOPRINE: AN ADDITIVE TOXIC EFFECT ON THE BONE MARROW" @default.
• W1997777254 doi "https://doi.org/10.1097/00005176-200406001-00820" @default.
• W1997777254 hasPublicationYear "2004" @default.
• W1997777254 type Work @default.
• W1997777254 sameAs 1997777254 @default.
• W1997777254 citedByCount "0" @default.
• W1997777254 crossrefType "journal-article" @default.
• W1997777254 hasAuthorship W1997777254A5009148625 @default.
• W1997777254 hasAuthorship W1997777254A5022234144 @default.
• W1997777254 hasAuthorship W1997777254A5032980660 @default.
• W1997777254 hasAuthorship W1997777254A5070536643 @default.
• W1997777254 hasConcept C126322002 @default.
• W1997777254 hasConcept C203014093 @default.
• W1997777254 hasConcept C2776581026 @default.
• W1997777254 hasConcept C2776760755 @default.
• W1997777254 hasConcept C2778660654 @default.
• W1997777254 hasConcept C2779134260 @default.
• W1997777254 hasConcept C2780007613 @default.
• W1997777254 hasConcept C2780817109 @default.
• W1997777254 hasConcept C2908647359 @default.
• W1997777254 hasConcept C29730261 @default.
• W1997777254 hasConcept C70917649 @default.
• W1997777254 hasConcept C71924100 @default.
• W1997777254 hasConcept C90924648 @default.
• W1997777254 hasConcept C99454951 @default.
• W1997777254 hasConceptScore W1997777254C126322002 @default.
• W1997777254 hasConceptScore W1997777254C203014093 @default.
• W1997777254 hasConceptScore W1997777254C2776581026 @default.
• W1997777254 hasConceptScore W1997777254C2776760755 @default.
• W1997777254 hasConceptScore W1997777254C2778660654 @default.
• W1997777254 hasConceptScore W1997777254C2779134260 @default.
• W1997777254 hasConceptScore W1997777254C2780007613 @default.
• W1997777254 hasConceptScore W1997777254C2780817109 @default.
• W1997777254 hasConceptScore W1997777254C2908647359 @default.
• W1997777254 hasConceptScore W1997777254C29730261 @default.
• W1997777254 hasConceptScore W1997777254C70917649 @default.
• W1997777254 hasConceptScore W1997777254C71924100 @default.
• W1997777254 hasConceptScore W1997777254C90924648 @default.
• W1997777254 hasConceptScore W1997777254C99454951 @default.
• W1997777254 hasIssue "Supplement 1" @default.
• W1997777254 hasLocation W19977772541 @default.
• W1997777254 hasOpenAccess W1997777254 @default.
• W1997777254 hasPrimaryLocation W19977772541 @default.
• W1997777254 hasRelatedWork W1978270674 @default.
• W1997777254 hasRelatedWork W1989435537 @default.
• W1997777254 hasRelatedWork W1997777254 @default.
• W1997777254 hasRelatedWork W2040498834 @default.
• W1997777254 hasRelatedWork W2132517981 @default.
• W1997777254 hasRelatedWork W2364831674 @default.
• W1997777254 hasRelatedWork W2979556179 @default.
• W1997777254 hasRelatedWork W2982182572 @default.
• W1997777254 hasRelatedWork W2187861540 @default.
• W1997777254 hasRelatedWork W3142130116 @default.
• W1997777254 hasVolume "39" @default.
• W1997777254 isParatext "false" @default.
• W1997777254 isRetracted "false" @default.
• W1997777254 magId "1997777254" @default.
• W1997777254 workType "article" @default.